DNL Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £19,955
Insider Selling (Last 12 Months): GBX 0

Diurnal Group Insider Trading History Chart

This chart shows the insider buying and selling history at Diurnal Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Diurnal Group Share Price & Price History

Current Price: GBX 26.92
Price Change: Price Decrease of -0.185 (-0.68%)
As of 09/28/2022 04:19 PM ET

This chart shows the closing price history over time for DNL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Diurnal Group Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2022Richard RossInsiderBuy153,500GBX 13£19,955
9/15/2021Richard BungayInsiderBuy19,386GBX 54£10,468.44
7/13/2021Martin WhitakerInsiderSell80,612GBX 63£50,785.56
5/12/2021Richard RossInsiderSell20,000GBX 67£13,400
10/29/2020Richard RossInsiderBuy3,668GBX 60£2,200.80
7/15/2020Richard BungayInsiderSell41,873GBX 30£12,561.90
4/6/2020Martin WhitakerInsiderBuy19,146GBX 29£5,552.34
3/27/2020Richard BungayInsiderBuy10,782GBX 37£3,989.34
12/16/2019Martin WhitakerInsiderBuy25,000GBX 30£7,500
10/21/2019Martin WhitakerInsiderSell230,152GBX 26£59,839.52
See Full Table

SEC Filings (Institutional Ownership Changes) for Diurnal Group (LON:DNL)

Diurnal Group logo
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.
Read More on Diurnal Group

Today's Range

Now: GBX 26.92
Low: 26.92
High: 26.93

50 Day Range

MA: GBX 16.92
Low: 9.59
High: 27

52 Week Range

Now: GBX 26.92
Low: 9.50
High: 67.90

Volume

148,867 shs

Average Volume

519,134 shs

Market Capitalization

£45.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Diurnal Group?

Diurnal Group's top insider shareholders include:
  1. Martin Whitaker (Insider)
  2. Richard Bungay (Insider)
  3. Richard Ross (Insider)
Learn More about top insider investors at Diurnal Group.